Final  ||| S:0 E:6 ||| JJ
report  ||| S:6 E:13 ||| NN
of  ||| S:13 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
safety  ||| S:20 E:27 ||| NN
assessment  ||| S:27 E:38 ||| NN
of  ||| S:38 E:41 ||| IN
Kojic  ||| S:41 E:47 ||| NNP
acid  ||| S:47 E:52 ||| NN
as  ||| S:52 E:55 ||| IN
used  ||| S:55 E:60 ||| VBN
in  ||| S:60 E:63 ||| IN
cosmetics  ||| S:63 E:73 ||| NNS
Kojic  ||| S:73 E:79 ||| JJ
acid  ||| S:79 E:84 ||| NN
functions  ||| S:84 E:94 ||| NNS
as  ||| S:94 E:97 ||| IN
an  ||| S:97 E:100 ||| DT
antioxidant  ||| S:100 E:112 ||| NN
in  ||| S:112 E:115 ||| IN
cosmetic  ||| S:115 E:124 ||| JJ
products ||| S:124 E:132 ||| NNS
.  ||| S:132 E:134 ||| .
Kojic  ||| S:134 E:140 ||| JJ
acid  ||| S:140 E:145 ||| NN
was  ||| S:145 E:149 ||| VBD
not  ||| S:149 E:153 ||| RB
a  ||| S:153 E:155 ||| DT
toxicant  ||| S:155 E:164 ||| NN
in  ||| S:164 E:167 ||| IN
acute ||| S:167 E:172 ||| JJ
,  ||| S:172 E:174 ||| ,
chronic ||| S:174 E:181 ||| NN
,  ||| S:181 E:183 ||| ,
reproductive ||| S:183 E:195 ||| JJ
,  ||| S:195 E:197 ||| ,
and  ||| S:197 E:201 ||| CC
genotoxicity  ||| S:201 E:214 ||| JJ
studies ||| S:214 E:221 ||| NNS
.  ||| S:221 E:223 ||| .
While  ||| S:223 E:229 ||| IN
some  ||| S:229 E:234 ||| DT
animal  ||| S:234 E:241 ||| NN
data  ||| S:241 E:246 ||| NNS
suggested  ||| S:246 E:256 ||| VBD
tumor  ||| S:256 E:262 ||| JJ
promotion  ||| S:262 E:272 ||| NN
and  ||| S:272 E:276 ||| CC
weak  ||| S:276 E:281 ||| JJ
carcinogenicity ||| S:281 E:296 ||| NN
,  ||| S:296 E:298 ||| ,
kojic  ||| S:298 E:304 ||| JJ
acid  ||| S:304 E:309 ||| NN
is  ||| S:309 E:312 ||| VBZ
slowly  ||| S:312 E:319 ||| RB
absorbed  ||| S:319 E:328 ||| VBN
into  ||| S:328 E:333 ||| IN
the  ||| S:333 E:337 ||| DT
circulation  ||| S:337 E:349 ||| NN
from  ||| S:349 E:354 ||| IN
human  ||| S:354 E:360 ||| JJ
skin  ||| S:360 E:365 ||| NN
and  ||| S:365 E:369 ||| CC
likely  ||| S:369 E:376 ||| RB
would  ||| S:376 E:382 ||| MD
not  ||| S:382 E:386 ||| RB
reach  ||| S:386 E:392 ||| VB
the  ||| S:392 E:396 ||| DT
threshold  ||| S:396 E:406 ||| NN
at  ||| S:406 E:409 ||| IN
which  ||| S:409 E:415 ||| WDT
these  ||| S:415 E:421 ||| DT
effects  ||| S:421 E:429 ||| NNS
were  ||| S:429 E:434 ||| VBD
seen ||| S:434 E:438 ||| VBN
.  ||| S:438 E:440 ||| .
The  ||| S:440 E:444 ||| DT
available  ||| S:444 E:454 ||| JJ
human  ||| S:454 E:460 ||| JJ
sensitization  ||| S:460 E:474 ||| JJ
data  ||| S:474 E:479 ||| NNS
supported  ||| S:479 E:489 ||| VBD
the  ||| S:489 E:493 ||| DT
safety  ||| S:493 E:500 ||| NN
of  ||| S:500 E:503 ||| IN
kojic  ||| S:503 E:509 ||| JJ
acid  ||| S:509 E:514 ||| NN
at  ||| S:514 E:517 ||| IN
a  ||| S:517 E:519 ||| DT
use  ||| S:519 E:523 ||| NN
concentration  ||| S:523 E:537 ||| NN
of  ||| S:537 E:540 ||| IN
2 ||| S:540 E:541 ||| CD
%  ||| S:541 E:543 ||| NN
in  ||| S:543 E:546 ||| IN
leave-on  ||| S:546 E:555 ||| JJ
cosmetics ||| S:555 E:564 ||| NNS
.  ||| S:564 E:566 ||| .
Kojic  ||| S:566 E:572 ||| JJ
acid  ||| S:572 E:577 ||| NN
depigmented  ||| S:577 E:589 ||| VBZ
black  ||| S:589 E:595 ||| JJ
guinea  ||| S:595 E:602 ||| NN
pig  ||| S:602 E:606 ||| NN
skin  ||| S:606 E:611 ||| NN
at  ||| S:611 E:614 ||| IN
a  ||| S:614 E:616 ||| DT
concentration  ||| S:616 E:630 ||| NN
of  ||| S:630 E:633 ||| IN
4 ||| S:633 E:634 ||| CD
% ||| S:634 E:635 ||| NN
,  ||| S:635 E:637 ||| ,
but  ||| S:637 E:641 ||| CC
this  ||| S:641 E:646 ||| DT
effect  ||| S:646 E:653 ||| NN
was  ||| S:653 E:657 ||| VBD
not  ||| S:657 E:661 ||| RB
seen  ||| S:661 E:666 ||| VBN
at  ||| S:666 E:669 ||| IN
1 ||| S:669 E:670 ||| CD
% ||| S:670 E:671 ||| NN
.  ||| S:671 E:673 ||| .
The  ||| S:673 E:677 ||| DT
Cosmetic  ||| S:677 E:686 ||| NNP
Ingredient  ||| S:686 E:697 ||| NNP
Review  ||| S:697 E:704 ||| NNP
( ||| S:704 E:705 ||| -LRB-
CIR ||| S:705 E:708 ||| NNP
)  ||| S:708 E:710 ||| -RRB-
Expert  ||| S:710 E:717 ||| NNP
Panel  ||| S:717 E:723 ||| NNP
concluded  ||| S:723 E:733 ||| VBD
that  ||| S:733 E:738 ||| IN
the  ||| S:738 E:742 ||| DT
2  ||| S:742 E:744 ||| CD
end  ||| S:744 E:748 ||| NN
points  ||| S:748 E:755 ||| NNS
of  ||| S:755 E:758 ||| IN
concern ||| S:758 E:765 ||| NN
,  ||| S:765 E:767 ||| ,
dermal  ||| S:767 E:774 ||| JJ
sensitization  ||| S:774 E:788 ||| NN
and  ||| S:788 E:792 ||| CC
skin  ||| S:792 E:797 ||| NN
lightening ||| S:797 E:807 ||| NN
,  ||| S:807 E:809 ||| ,
would  ||| S:809 E:815 ||| MD
not  ||| S:815 E:819 ||| RB
be  ||| S:819 E:822 ||| VB
seen  ||| S:822 E:827 ||| VBN
at  ||| S:827 E:830 ||| IN
use  ||| S:830 E:834 ||| NN
concentrations  ||| S:834 E:849 ||| NNS
below  ||| S:849 E:855 ||| IN
1 ||| S:855 E:856 ||| CD
% ||| S:856 E:857 ||| NN
;  ||| S:857 E:859 ||| :
therefore ||| S:859 E:868 ||| RB
,  ||| S:868 E:870 ||| ,
this  ||| S:870 E:875 ||| DT
ingredient  ||| S:875 E:886 ||| NN
is  ||| S:886 E:889 ||| VBZ
safe  ||| S:889 E:894 ||| JJ
for  ||| S:894 E:898 ||| IN
use  ||| S:898 E:902 ||| NN
in  ||| S:902 E:905 ||| IN
cosmetic  ||| S:905 E:914 ||| JJ
products  ||| S:914 E:923 ||| NNS
up  ||| S:923 E:926 ||| RB
to  ||| S:926 E:929 ||| TO
that  ||| S:929 E:934 ||| DT
level ||| S:934 E:939 ||| NN
.  ||| S:939 E:941 ||| .
